ソレイジア・ファーマ株式会社│がんと向き合う人たちのために

This page presents Solasia Pharma K.K., a pharmaceutical company specializing in cancer treatment. The company aims to illuminate the future for cancer patients by understanding unspoken patient needs and developing innovative medicines. Key strengths include deep expertise in oncology, understanding patient perspectives, and agile decision-making. Approved products include Sancuso® for chemotherapy-induced nausea/vomiting, Darvadstrocel® for peripheral T-cell lymphoma, and Episil® for chemotherapy-induced oral mucositis. Pipeline candidates include SP-04 for peripheral neuropathy and SP-05 for colorectal cancer, with development progressing across multiple regions.